Invest in Standardization

April 2022 - Vol.19 No. 4 - Page #1

Seeking standardization in pharmacy practice is an ongoing challenge given the breadth of affected areas—from the adoption of ENFit devices for enteral feeding to updating smart pump drug libraries for EHR integrations. Standardization efforts are further tested by the omnipresence of drug shortages putting pressure on operating efficiency. Consider how the current heparin shortage has made clear the imperative need for access to standardized stability data.

The lack of standardization (and the associated impacts) on pharmacy practice is particularly evident when integrating new pharmacies into a health system, with perhaps the clearest evidence being seen in the cleanroom. When compounding the same product, two facilities may have different recipes, differing compounding steps or order of steps, and they may rely on different resources for stability dating. These inconsistencies can then lead to the application of differing beyond use dates (BUDs) for the same product, which further underscores the need for standardization in compounding processes.

Extrapolating this idea further, for hospitals without a robust drug information team, limited access to stability data may result in excessively conservative BUDs, and thus increased waste. Naturally, the case for standardization depends on the ability to reduce waste and increase efficiencies, thus establishing a system for ensuring standardized stability data should be a focus for all pharmacy operations.

In this month’s issue, Matthew Wolf, PharmD, of Wake Forest Baptist Hospital shares his facility’s approach to standardizing BUD assignments (see page 20). This is one excellent example of the thoughtful development of consistent, standardized processes that ultimately help ensure the safe delivery of effective medications to the patient.

All the best,

R. Mitchell Halvorsen

Publisher

Correction:

In PP&P’s February 2022 Unit Dose Market Watch, page 6, a mistake was included in Arbor Pharmaceuticals’ Nymalize listing. The correct information is as follows:

• Dosage Strength: 30 mg/5 mL, NDC Number: 244338-230-12

• Dosage Strength: 60 mg/10 mL, NDC Number: 244338-260-12

The image included was also incorrect; the correct version is available here pppmag.com/article/2873. PP&P regrets this error.

Login

Like what you've read? Please log in or create a free account to enjoy more of what www.pppmag.com has to offer.

Current Issue